This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; NCA; CD66c)	<p>Cell culture studies suggest inhibiting CEACAM6 could help improve immunotherapy treatments for MM. In the study, T cells cultured with MM cells showed comparable reactivity and cytotoxicity to T cells cultured alone. In the cell lines and in patient samples, an anti-CEACAM6 mAb or small interfering RNA against the antigen restored T cell reactivity and cytotoxicity against MM cells, whereas control mAbs or siRNA did not. Next steps could include evaluating an anti-CEACAM6 mAb in combination with T cell immunotherapy in MM models.</p> <p>At least three companies have CEACAM6-targeting antibodies in preclinical development to treat various solid cancers.</p> <p>SciBX 6(19); doi:10.1038/scibx.2013.467 Published online May 16, 2013</p>	Patent and licensing status unavailable	<p>Witzens-Harig, M. <i>et al. Blood</i>; published online April 19, 2013; doi:10.1182/blood-2012-05-429415</p> <p>Contact: Philipp Beckhove, German Cancer Research Center, Heidelberg, Germany e-mail: p.beckhove@dkfz.de</p>